News

Bristol Myers' heart disease drug fails to meet main goals in late-stage study
(Reuters) -Bristol Myers Squibb's drug to treat a type of heart disease did not significantly improve functional capacity and ...
FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight
IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...
Soleno Therapeutics Announces VYKAT(TM) XR Launch
INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...